PDS Biotechnology Co. (NASDAQ:PDSB) Short Interest Down 17.3% in March

PDS Biotechnology Co. (NASDAQ:PDSB) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 3,860,000 shares, a decrease of 17.3% from the February 28th total of 4,670,000 shares. Based on an average trading volume of 614,400 shares, the days-to-cover ratio is currently 6.3 days. Approximately 11.4% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, PDS Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

PDS Biotechnology Trading Down 9.2 %

Shares of PDSB stock traded down $0.11 during mid-day trading on Tuesday, reaching $1.08. 484,944 shares of the stock traded hands, compared to its average volume of 528,997. The company has a market cap of $41.25 million, a price-to-earnings ratio of -0.93 and a beta of 1.68. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock’s fifty day simple moving average is $1.40 and its two-hundred day simple moving average is $2.13. PDS Biotechnology has a 1-year low of $1.09 and a 1-year high of $4.42.

PDS Biotechnology (NASDAQ:PDSB) last announced its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. On average, research analysts anticipate that PDS Biotechnology will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in PDS Biotechnology in the fourth quarter worth $26,000. Jane Street Group LLC bought a new position in shares of PDS Biotechnology during the 4th quarter worth about $58,000. Marshall Wace LLP boosted its position in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology in the 4th quarter valued at about $89,000. Finally, Two Sigma Investments LP increased its position in PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after buying an additional 48,132 shares in the last quarter. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.